Terms: = Leukemia AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Treatment
193 results:
1. Assessment of the FRET-based Teen sensor to monitor ERK activation changes preceding morphological defects in a RASopathy zebrafish model and phenotypic rescue by MEK inhibitor.
Fasano G; Petrini S; Bonavolontà V; Paradisi G; Pedalino C; Tartaglia M; Lauri A
Mol Med; 2024 Apr; 30(1):47. PubMed ID: 38594640
[TBL] [Abstract] [Full Text] [Related]
2. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
Li X; Lin S; Liao N; Mai H; Long X; Liu L; Wu B; Chen Q; Kong Q; Kong X; Liu L; Qin J; Fang J; Zhou D
Hematol Oncol; 2024 May; 42(3):e3265. PubMed ID: 38564328
[TBL] [Abstract] [Full Text] [Related]
3. [FLT3-ITD mutation-positive acute myeloid leukemia undergoing clonal transition with ptpn11 mutation at relapse].
Kurihara K; Sadato D; Najima Y; Hirama C; Haraguchi K; Kato K; Kondo K; Sadaga Y; Kato C; Sakai S; Kambara Y; Nabe Y; Teshima K; Asano K; Jinguji A; Shimabukuro M; Ouchi F; Inai K; Koi S; Shingai N; Toya T; Shimizu H; Kobayashi T; Oboki K; Harada H; Okuyama Y; Harada Y; Doki N
Rinsho Ketsueki; 2024; 65(2):63-68. PubMed ID: 38447999
[TBL] [Abstract] [Full Text] [Related]
4. Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.
Scott MT; Liu W; Mitchell R; Clarke CJ; Kinstrie R; Warren F; Almasoudi H; Stevens T; Dunn K; Pritchard J; Drotar ME; Michie AM; Jørgensen HG; Higgins B; Copland M; Vetrie D
Nat Commun; 2024 Jan; 15(1):651. PubMed ID: 38246924
[TBL] [Abstract] [Full Text] [Related]
5. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
6. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
Pastore F; Gittinger H; Raab S; Tschuri S; Ksienzyk B; Konstandin NP; Schneider S; Rothenberg-Thurley M; Horny HP; Werner M; Sauerland MC; Amler S; Görlich D; Berdel WE; Wörmann B; Braess J; Hiddemann W; Tischer J; Herold T; Metzeler KH; Spiekermann K
Br J Haematol; 2023 Sep; 202(6):1165-1177. PubMed ID: 37455345
[TBL] [Abstract] [Full Text] [Related]
7. 6-Mercaptopurine potently inhibits recruitment of shp2 by phosphorylated PD-1 to inhibit PD-1 signalling and enhance T cell function.
Liu L; Lei Y; Zheng Z; Zhou X; Chen S; Zeng G; Yu L; Wang P; Chen L
Immunology; 2023 Oct; 170(2):230-242. PubMed ID: 37259771
[TBL] [Abstract] [Full Text] [Related]
8. Sunitinib selectively targets leukemogenic signaling of mutant shp2 in juvenile myelomonocytic leukemia.
He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
[TBL] [Abstract] [Full Text] [Related]
9. The effects of large-volume leukapheresis on hemoglobin, platelet and coagulation in patients with hyperleukocytic leukemia.
Liu L; Chen L; Zhao C; Fan R; Tang Q; Yuan Q; Du W; Liu X
Clin Hemorheol Microcirc; 2023; 84(3):275-281. PubMed ID: 37092218
[TBL] [Abstract] [Full Text] [Related]
10. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Richard-Carpentier G; Rausch CR; Sasaki K; Hammond D; Morita K; Takahashi K; Tang G; Kanagal-Shamanna R; Bhalla K; Dinardo CD; Borthakur G; Pemmaraju N; Shpall EJ; Alousi A; Daver NG; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM; Kadia TM
Haematologica; 2023 Sep; 108(9):2331-2342. PubMed ID: 36951163
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical Study on the Relationship between Gene Mutation Profile and Prognosis in Pediatric Acute Lymphocyte leukemia].
Chen Y; Qi SS; Ding LL; DU Y; Song N; Wang Z; Yang L; Sun M; Xiong H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):17-24. PubMed ID: 36765471
[TBL] [Abstract] [Full Text] [Related]
12. Potential clinical use of azacitidine and MEK inhibitor combination therapy in ptpn11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract] [Full Text] [Related]
13. Spectrum and clinical features of gene mutations in Chinese pediatric acute lymphoblastic leukemia.
Shen D; Liu L; Xu X; Song H; Zhang J; Xu W; Zhao F; Liang J; Liao C; Wang Y; Xia T; Wang C; Lou F; Cao S; Qin J; Tang Y
BMC Pediatr; 2023 Feb; 23(1):62. PubMed ID: 36739388
[TBL] [Abstract] [Full Text] [Related]
14. Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells.
Dudka W; Hoser G; Mondal SS; Turos-Korgul L; Swatler J; Kusio-Kobialka M; Wołczyk M; Klejman A; Brewinska-Olchowik M; Kominek A; Wiech M; Machnicki MM; Seferynska I; Stoklosa T; Piwocka K
BMC Cancer; 2022 Dec; 22(1):1254. PubMed ID: 36460969
[TBL] [Abstract] [Full Text] [Related]
15. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the treatment of IDH2- and FLT3-Mutated Acute Myeloid leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract] [Full Text] [Related]
16. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
[TBL] [Abstract] [Full Text] [Related]
17. Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial.
Yen R; Grasedieck S; Wu A; Lin H; Su J; Rothe K; Nakamoto H; Forrest DL; Eaves CJ; Jiang X
Leukemia; 2022 Oct; 36(10):2443-2452. PubMed ID: 35999259
[TBL] [Abstract] [Full Text] [Related]
18. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N; Jahn E; Saadati M; Bullinger L; Larson RA; Ottone T; Amadori S; Prior TW; Brandwein JM; Appelbaum FR; Medeiros BC; Tallman MS; Ehninger G; Heuser M; Ganser A; Pallaud C; Gathmann I; Krzykalla J; Benner A; Bloomfield CD; Thiede C; Stone RM; Döhner H; Döhner K
Leukemia; 2022 Sep; 36(9):2218-2227. PubMed ID: 35922444
[TBL] [Abstract] [Full Text] [Related]
19. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating shp2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract] [Full Text] [Related]
20. Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.
Ramdas B; Yuen LD; Palam LR; Patel R; Pasupuleti SK; Jideonwo V; Zhang J; Maguire C; Wong E; Kanumuri R; Zhang C; Sandusky G; Chan RJ; Zhang C; Stieglitz E; Haneline L; Kapur R
Mol Ther; 2022 Jul; 30(7):2505-2521. PubMed ID: 35443935
[TBL] [Abstract] [Full Text] [Related]
[Next]
